<unk>  is indicated for the topical treatment of acne vulgaris in females and males age 12 years and older. It is applied to the affected skin area in a dose of 1 g cream (or 10 mg<unk>  twice per day, once in the morning and once in the evening. The medication should not be used ophthalmically, orally, or vaginally. Two large phase 3 randomized controlled trials evaluated the effectiveness of<unk>  for the treatment of acne over a period of 12 weeks.<unk>  decreased acne symptoms by about 8 to 18% more than placebo. The defined treatment success endpoint was achieved in about 18 to 20% of individuals with<unk>  relative to about 7 to 9% of individuals with placebo. The comparative effectiveness of<unk>  between males and females was not described. A small pilot randomized controlled trial in 2011 found that<unk>  cream decreased acne symptoms to a similar or significantly greater extent than tretinoin 0.05% cream. No active comparator was used in the phase III clinical trials of<unk>  for acne. Hence, it's unclear how<unk>  compares to other therapies used in the treatment of acne. Available forms<unk>  is available in the form of a 1% (10 mg/g) cream for topical use.
Clascoterone
Silodosin
Doxazosin
Spirorenone
Canrenone
Acebutolol
Azaperone
Finerenone